InVitro International (IVRO)
USD 0.1
(0.0%)
USD 0.1
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 661.32 Thousand USD | -17.02% |
| 2022 | 796.96 Thousand USD | -4.1% |
| 2021 | 830.99 Thousand USD | -4.07% |
| 2020 | 866.24 Thousand USD | 7.87% |
| 2019 | 803.07 Thousand USD | 24.06% |
| 2018 | 647.31 Thousand USD | -1.88% |
| 2017 | 659.74 Thousand USD | 12.1% |
| 2016 | 588.53 Thousand USD | 0.14% |
| 2015 | 587.72 Thousand USD | 9.74% |
| 2014 | 535.57 Thousand USD | 0.0% |
| 1996 | 2.6 Million USD | -25.71% |
| 1995 | 3.5 Million USD | -36.36% |
| 1994 | 5.5 Million USD | 19.57% |
| 1993 | 4.6 Million USD | -24.59% |
| 1992 | 6.1 Million USD | 79.41% |
| 1991 | 3.4 Million USD | 325.0% |
| 1990 | 800 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 155.35 Thousand USD | 44.25% |
| 2024 Q2 | 133.85 Thousand USD | -13.84% |
| 2024 Q3 | 130.64 Thousand USD | -2.4% |
| 2023 Q2 | 174.77 Thousand USD | -12.81% |
| 2023 Q4 | 107.69 Thousand USD | -39.64% |
| 2023 Q1 | 200.44 Thousand USD | -9.55% |
| 2023 Q3 | 178.41 Thousand USD | 2.08% |
| 2023 FY | 661.32 Thousand USD | -17.02% |
| 2022 Q3 | 183.17 Thousand USD | -1.82% |
| 2022 FY | 796.96 Thousand USD | -4.1% |
| 2022 Q1 | 205.59 Thousand USD | -6.37% |
| 2022 Q2 | 186.56 Thousand USD | -9.26% |
| 2022 Q4 | 221.61 Thousand USD | 20.98% |
| 2021 Q2 | 215.41 Thousand USD | 0.0% |
| 2021 FY | 830.99 Thousand USD | -4.07% |
| 2021 Q4 | 219.58 Thousand USD | 26.59% |
| 2021 Q3 | 173.46 Thousand USD | -19.48% |
| 2020 FY | 866.24 Thousand USD | 7.87% |
| 2019 FY | 803.07 Thousand USD | 24.06% |
| 2018 FY | 647.31 Thousand USD | -1.88% |
| 2017 FY | 659.74 Thousand USD | 12.1% |
| 2016 FY | 588.53 Thousand USD | 0.14% |
| 2015 FY | 587.72 Thousand USD | 9.74% |
| 2014 FY | 535.57 Thousand USD | 0.0% |
| 1997 Q2 | 462 Thousand USD | 0.0% |
| 1997 Q3 | 280 Thousand USD | -39.39% |
| 1997 Q1 | - USD | -100.0% |
| 1996 Q3 | 500 Thousand USD | -16.67% |
| 1996 Q4 | 800 Thousand USD | 60.0% |
| 1996 Q1 | 600 Thousand USD | 114.63% |
| 1996 Q2 | 600 Thousand USD | 0.0% |
| 1996 FY | 2.6 Million USD | -25.71% |
| 1995 Q2 | - USD | 0.0% |
| 1995 FY | 3.5 Million USD | -36.36% |
| 1995 Q4 | -4.1 Million USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q1 | - USD | -100.0% |
| 1994 Q4 | 1.6 Million USD | 23.08% |
| 1994 Q1 | 1.4 Million USD | 16.67% |
| 1994 Q2 | 1.1 Million USD | -21.43% |
| 1994 Q3 | 1.3 Million USD | 18.18% |
| 1994 FY | 5.5 Million USD | 19.57% |
| 1993 Q1 | 900 Thousand USD | -43.75% |
| 1993 Q3 | 1.2 Million USD | 0.0% |
| 1993 Q4 | 1.2 Million USD | 0.0% |
| 1993 FY | 4.6 Million USD | -24.59% |
| 1993 Q2 | 1.2 Million USD | 33.33% |
| 1992 Q2 | 1.6 Million USD | 0.0% |
| 1992 FY | 6.1 Million USD | 79.41% |
| 1992 Q4 | 1.6 Million USD | -5.88% |
| 1992 Q3 | 1.7 Million USD | 6.25% |
| 1992 Q1 | - USD | -100.0% |
| 1991 Q3 | 700 Thousand USD | 158.33% |
| 1991 FY | 3.4 Million USD | 325.0% |
| 1991 Q4 | 900 Thousand USD | 28.57% |
| 1991 Q2 | -1.2 Million USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1990 Q2 | -700 Thousand USD | 0.0% |
| 1990 FY | 800 Thousand USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q3 | - USD | 100.0% |
| 1990 Q4 | - USD | 0.0% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q4 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | 36.957% |
| Arrayit Corporation | 6.19 Million USD | 89.329% |
| Atlantic International Corp. | 5.57 Million USD | 88.145% |
| Biocept, Inc. | 29.4 Million USD | 97.751% |
| Bioqual, Inc. | 7.44 Million USD | 91.122% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | 14.352% |
| DermTech, Inc. | 104.01 Million USD | 99.364% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 99.603% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 97.077% |
| iMD Companies, Inc. | 151.8 Thousand USD | -335.629% |
| IDenta Corp. | 662.97 Thousand USD | 0.249% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 96.731% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -1600.892% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 90.683% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -1038.016% |
| Medical Imaging Corp. | 1.91 Million USD | 65.415% |
| NovelStem International Corp. | 3.53 Million USD | 81.307% |
| Optigenex Inc. | 1.28 Million USD | 48.65% |
| PharmChem, Inc. | 2.93 Million USD | 77.439% |
| Proteome Sciences plc | 3.26 Million USD | 79.764% |
| Response Genetics, Inc | 25.31 Million USD | 97.388% |
| Rennova Health, Inc. | 7.67 Million USD | 91.387% |
| RushNet, Inc. | 1.78 Million USD | 63.04% |
| ScreenPro Security Inc. | 3.23 Million USD | 79.582% |
| Stella Diagnostics Inc. | 11.42 Million USD | 94.213% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 90.994% |
| Todos Medical Ltd. | 14.05 Million USD | 95.296% |